Loading
RNA Interference and Gene Delivery / Nanoplatforms for Cancer Theranostics · Journal article
Acs Applied Bio Materials · September 8, 2026
Raises a question worth testing. It does not answer one.
This is an early-stage mechanistic study reporting a novel dual-modality nanoplatform (siRNA-loaded and photothermal-loaded macrophage-membrane-coated nanoparticles) in a cell model of chronic HBV infection. Sequential administration achieved reduction in viral markers and cccDNA in vitro, with acceptable biosafety profiles, but the work remains preclinical and does not address efficacy in animals or humans.
In vitro mechanistic study using cell models of chronic HBV infection. In vitro cell model of chronic HBV infection. Intervention: Sequential administration of siRNA-loaded macrophage-membrane-coated lipid nanoparticles (siR@HM NPs) followed 72 hours later by photothermal agent-loaded macrophage-membrane-coated PLGA nanoparticles (TPAT@HM NPs) with 808 nm near-infrare…. Compared with: Concurrent administration of both nanoparticles and single-agent (monotherapy) treatments.
Sequential administration of siR@HM NPs followed by TPAT@HM NPs yielded superior antiviral efficacy compared with concurrent administration or monotherapy alone in cell models. Sequential therapy reduced HBsAg, HBeAg, HBV DNA, cccDNA, and pgRNA levels in chronically infected hepatocytes. Biosafety assessments confirmed negligible cytotoxicity, hemolysis, and systemic toxicity in cell and in vitro assays.
Study is limited to in vitro cell models; no in vivo efficacy, toxicology, or pharmacokinetics reported. Biosafety assessments confirmed negligible cytotoxicity, hemolysis, and systemic toxicity in cell and in vitro assays.
This preclinical concept does not yet inform clinical practice. Substantial in vivo efficacy, safety, and pharmacokinetic work in animal models would be required before clinical translation can be considered.
This is an exploratory in vitro proof-of-concept study of a novel nanoplatform combining siRNA and photothermal therapy; it demonstrates mechanism in cell models but lacks in vivo efficacy data, clinical translation, or direct comparison to standard antiviral therapy.
As stated by the source record.
Quoted from the source exactly as published.
This preclinical concept does not yet inform clinical practice. Substantial in vivo efficacy, safety, and pharmacokinetic work in animal models would be required before clinical translation can be considered.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Chronic hepatitis B (CHB) afflicts approximately 254 million people worldwide and is responsible for more than one million deaths annually. Intrahepatic persistence of covalently closed circular DNA (cccDNA), the episomal transcriptional template of hepatitis B virus (HBV), sustains chronic replication, blunts the efficacy of antiviral therapy, and precipitates virological relapse once treatment is discontinued. While emerging cccDNA-targeted strategies include CRISPR/Cas9-mediated cleavage and epigenetic silencing, their clinical translation is impeded by delivery inefficiency, safety concerns, and limited durability. Herein, we present a sequential nano-therapeutic platform that combines small interfering RNA (siRNA) delivery using HBV-pre-activated macrophage membranes (HMs) with photothermal therapy utilizing aggregation-induced emission (AIE) agents. In the first step, HM-coated lipid nanoparticles encapsulating siRNA (siR@HM NPs) enable virus to neutralize and hepatocyte targeted delivery via surface viral receptors, achieving efficient gene silencing. At 72 h post-administration, HM-coated PLGA nanoparticles loaded with an AIE photothermal agent (TPAT@HM NPs) are introduced, facilitating near-infrared IIb fluorescence-guided 808 nm laser ablation of residual infected cells. In a cell model of chronic HBV infection, both siR@HM NPs and TPAT@HM NPs achieved targeted delivery to infected hepatocytes. Critically, sequential administration yielded superior antiviral efficacy compared with concurrent administration or either monotherapy, leading to substantial reduction in HBsAg, HBeAg, HBV DNA, cccDNA, and pgRNA levels. Biosafety assessments confirmed negligible cytotoxicity, hemolysis, and systemic toxicity. This bionic platform integrates time-programmed virus targeting, RNA interference, and photothermal ablation. The virus-preactivated membrane coating enables dual recognition of both viral particles and infected cells, offering a precise and scalable theranostic strategy for HBV and other refractory viral infections.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.